Search
Results: 7092
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J Coles, Jeffrey A Cohen, Edward J Fox, Gavin Giovannoni, Hans-Peter Hartung, Eva Havrdova, Sven Schippling, Krzysztof W Selmaj, Anthony Traboulsee, D Alastair S Compston, David H Margolin, Karthinathan Thangavelu, Madalina C Chirieac, Darlene Jody, Panos Xenopoulos, Richard J Hogan, Michael A Panzara, Douglas L Arnold, CARE-MS II and CAMMS03409 Investigators
Dec 11, 2017
OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and Rebif...
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
G Giovannoni, JA Cohen, AJ Coles, H-P Hartung, E Havrdova, KW Selmaj, DH Margolin, SL Lake, SM Kaup, MA Panzara, DAS Compston, CARE-MS II Investigators
Jan 11, 2017
Adjuvants Immunologic Alemtuzumab Analysis of Variance Antibodies Monoclonal Humanized Antineoplastic Agents Disability Evaluation Disabled Persons Female Humans Interferon-beta Kaplan-Meier Estimate Longitudinal Studies Male Multiple Sclerosis Relapsing-Remitting Severity of Illness Index Treatment Outcome
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
Efficacy and safety of alemtuzumab over 6 years
Alasdair J Coles, Douglas L Arnold, Ann D Bass, Aaron L Boster, D Alastair S Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C Chirieac, Krzysztof W Selmaj
Jun 27, 2021
BACKGROUND: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous...
Infection risk with alemtuzumab decreases over time
Sibyl Wray, Eva Havrdova, David R Snydman, Douglas L Arnold, Jeffrey A Cohen, Alasdair J Coles, Hans-Peter Hartung, Krzysztof W Selmaj, Howard L Weiner, Nadia Daizadeh, David H Margolin, Madalina C Chirieac, D Alastair S Compston
Nov 22, 2018
BACKGROUND: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and...
An evaluation of the clinical and cost-effectiveness of alternative care locations for critically ill adult patients with acute traumatic brain injury.
R Grieve, Z Sadique, M Gomes, M Smith, FE Lecky, PJA Hutchinson, DK Menon, KM Rowan, DA Harrison, Risk Adjustment In Neurocritical care (RAIN) Study Investigators
Jun 25, 2018
BACKGROUND: For critically ill adult patients with acute traumatic brain injury (TBI), we assessed the clinical and cost-effectiveness of: (a) Management in dedicated neurocritical care units versus combined neuro/general...
Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care
Peter Le Roux, David K Menon, Giuseppe Citerio, Paul Vespa, Mary Kay Bader, Gretchen M Brophy, Michael N Diringer, Nino Stocchetti, Walter Videtta, Rocco Armonda, Neeraj Badjatia, Julian Böesel, Randall Chesnut, Sherry Chou, Jan Claassen, Marek Czosnyka, Michael De Georgia, Anthony Figaji, Jennifer Fugate, Raimund Helbok, David Horowitz, Peter Hutchinson, Monisha Kumar, Molly McNett, Chad Miller, Andrew Naidech, Mauro Oddo, DaiWai Olson, Kristine O'Phelan, J Javier Provencio, Corinna Puppo, Richard Riker, Claudia Robertson, Michael Schmidt, Fabio Taccone, Neurocritical Care Society, European Society of Intensive Care Medicine
Jan 09, 2019
Neurocritical care depends, in part, on careful patient monitoring but as yet there are little data on what processes are the most important to monitor, how these should be monitored, and whether monitoring these processes is...
ECCO Essential Requirements for Quality Cancer Care
Ian Banks, David Weller, Mehmet Ungan, Peter Selby, Matti Aapro, Marc Beishon, Marije Bolt, Fiona Bonanno, Claire Champeix, Csaba Dégi, Lisa Jelf Eneqvist, Joanna Kazmierska, Agnieszka Kolacinska, Simon Malas, Sébastien Moine, Danica Rotar Pavlic, Richard Price, Fiona Walter, Lynda Wyld
Sep 05, 2019
ECCO Essential Requirements for Quality Cancer Care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to cancer patients. They are written by European experts...
Measurement of the total angiotensinogen and its reduced and oxidised forms in human plasma using targeted LC-MS/MS.
Lina A Dahabiyeh, David Tooth, Robin W Carrell, Randy J Read, Yahui Yan, Fiona Broughton Pipkin, David A Barrett
Dec 11, 2018
Angiotensinogen (AGT) is a critical protein in the renin-angiotensin-aldosterone system and may have an important role in the pathogenesis of pre-eclampsia. The disulphide linkage between cysteines 18 and 138 has a key role in...
Integrating care
BACKGROUND:As diabetes prevalence rises world-wide, the arrangement of clinics and care packages is increasingly debated by health care professionals (HCPs), health service researchers, patient groups and policy makers....
Published by: BMC health services research
Integrating care
BACKGROUND: As diabetes prevalence rises world-wide, the arrangement of clinics and care packages is increasingly debated by health care professionals (HCPs), health service researchers, patient groups and policy makers....
Diabetes Healthcare Assistants integrated care Qualitative administrative personnel Adult Aged Decision Making Delivery of Health Care Integrated Diabetes mellitus Female Health Personnel Health Services Research Humans Interviews as Topic Male Middle Aged Observation Patient Participation qualitative research
Integrating care
Abstract: Background: As diabetes prevalence rises world-wide, the arrangement of clinics and care packages is increasingly debated by health care professionals (HCPs), health service researchers, patient groups and policy...
Alemtuzumab CARE-MS II 5-year follow-up
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, S Schippling, KW Selmaj, A Traboulsee, AS Compston, DH Margolin, K Thangavelu, MC Chirieac, D Jody, P Xenopoulos, RJ Hogan, MA Panzara, DL Arnold
Sep 11, 2017
Neurodegenerative Neurosciences Multiple Sclerosis Brain Disorders Clinical Research Autoimmune Disease Neurological Alemtuzumab Antibodies Monoclonal Humanized Atrophy Brain Disability Evaluation Follow-Up Studies Humans Immunologic Factors Kaplan-Meier Estimate Multiple Sclerosis Relapsing-Remitting Organ Size Time Factors Treatment Outcome
Beginning and duration of pregnancy in automated health care databases
Andrea V. Margulis, Kristin Palmsten, Susan E. Andrade, Rachel A. Charlton, Janet R. Hardy, William O. Cooper, Sonia Hernández-Díaz
Apr 01, 2015
Purpose: To describe methods reported in the literature to estimate the beginning or duration of pregnancy in automated health care data, and to present results of validation exercises where available. Methods: Papers...
Beginning and duration of pregnancy in automated health care databases
Andrea V. Margulis, Kristin Palmsten, Susan E. Andrade, Rachel A. Charlton, Janet R. Hardy, William O. Cooper, Sonia Hernández-Díaz
Apr 01, 2015
Purpose: To describe methods reported in the literature to estimate the beginning or duration of pregnancy in automated health care data, and to present results of validation exercises where available. Methods: Papers...
MS in South Asians in England
Richard S Nicholas, Vassiliki Kostadima, Maya Hanspal, Benjamin R Wakerley, Ruhena Sergeant, Saskia Decuypere, Omar Malik, Rosemary J Boyton, Daniel M Altmann
Sep 29, 2016
BACKGROUND: Epidemiological studies describe a latitude gradient for increased MS prevalence and a preponderance of disease in Caucasian individuals. However, individuals from other ethnic backgrounds and low-risk regions can...
Differences in access to Emergency Paediatric Intensive Care and care during Transport (DEPICT)
Padmanabhan Ramnarayan, Ruth Evans, Elizabeth S Draper, Sarah E Seaton, Jo Wray, Stephen Morris, Christina Pagel, DEPICT Study Investigators
Nov 17, 2020
INTRODUCTION: Following centralisation of UK paediatric intensive care, specialist retrieval teams were established who travel to general hospitals to stabilise and transport sick children to regional paediatric intensive care...
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of...
continuous tumour shrinkage endpoints longitudinal model phase II cancer trial Clinical Trials Phase II as Topic Colonic Neoplasms Computer Simulation Disease Progression Endpoint Determination Humans Logistic Models Medical Oncology Neoplasms Randomized Controlled Trials as Topic Research Design Treatment Outcome
An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH)
Catherine M Sackley, Marion F Walker, Christopher R Burton, Caroline L Watkins, Jonathan Mant, Andrea K Roalfe, Keith Wheatley, Bart Sheehan, Leslie Sharp, Katie E Stant, Joanna Fletcher-Smith, Kerry Steel, Garry R Barton, Lisa Irvine, Guy Peryer, OTCH investigators
May 02, 2018
BACKGROUND: Care home residents with stroke-related disabilities have significant activity limitations. Phase II trial results suggested a potential benefit of occupational therapy (OT) in maintaining residents' capacity to...
LC–MS Lipidomics
Typical lipidomics methods incorporate a liquid−liquid extraction with LC−MS quantitation; however, the classic sample extraction methods are not high-throughput and do not perform well at extracting the full range of lipids...
Preliminary pharmacokinetic study of the anticancer 6BIO in mice using an UHPLC-MS/MS approach
Job Tchoumtchoua, Maria Halabalaki, Evangelos Gikas, Anthony Tsarbopoulos, Nikoletta Fotaki, Lucy Liu, Sangkil Nam, Richard Jove, Leandros A. Skaltsounis
Feb 05, 2019
Indirubins represent a group of natural and synthetic products with bio-activities against numerous human cancer cell lines acting by inhibiting protein kinases. The natural sources of indirubins are plants of Isatis sp....
The Primary Care Spend Model
Robert Baillieu, Michael Kidd, Robert Phillips, Martin Roland, Michael Mueller, David Morgan, Bruce Landon, Jennifer DeVoe, Viviana Martinez-Bianchi, Hong Wang, Rebecca Etz, Chris Koller, Neha Sachdev, Hannah Jackson, Yalda Jabbarpour, Andrew Bazemore
Aug 08, 2019
Increased investment in primary care is associated with lower healthcare costs and improved population health. The allocation of scarce resources should be driven by robust models that adequately describe primary care activities...
Oxidative Addition to Sn(II) Guanidinate Complexes
SnS, SnSe and SnTe are potentially important semiconductor materials. Here, we describe the application of chalcogen containing Sn IV guanidinate precursors for the production of tin(II) chalcogenide nanocrystals....
Provision of palliative and end-of-life care in UK care homes during the COVID-19 pandemic
Andy Bradshaw, Sophia Ostler, Claire Goodman, Izabele Batkovskyte, Clare Ellis-Smith, India Tunnard, Anna E Bone, Stephen Barclay, Martin Vernon, Irene J Higginson, Catherine J Evans, Katherine E Sleeman
Apr 17, 2023
Introduction
Little consideration has been given to how the provision of palliative and end-of-life care in care homes was affected by COVID-19. The aims of this study were to: (i) investigate the response of UK care...
Policy Palliative Care care homes end-of-life care mixed methods observational covid-19 Humans Terminal Care Cross-Sectional Studies Pandemics United Kingdom covid-19
Published by: Frontiers in public health
|
|< |
< |
1 |